Abacus FCF Advisors’s Royalty Pharma RPRX Stock Holding History

Abacus FCF Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-12,782	Closed	-$498K	–	175
2022 Q1	$498K	Buy	+12,782	New	+$502K	0.17%	176

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

SGA

Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

Abacus FCF Advisors's RPRX Position: Q2 2022 in Review

Abacus FCF Advisors sold out of Royalty Pharma (RPRX) in Q2 2022, closing a stake of 12,782 shares — an estimated $498K sold.

Abacus FCF Advisors first reported a position in RPRX in Q1 2022 and held it in 1 quarter. The position peaked at $498K in Q1 2022. 283 funds tracked by Wall St. Rank hold RPRX as of Q2 2022.

Abacus FCF Advisors reported no remaining Royalty Pharma position as of Q2 2022 after selling out during the quarter.
Abacus FCF Advisors sold 12,782 Royalty Pharma shares in Q2 2022, an estimated $498K.
Abacus FCF Advisors first reported a position in Royalty Pharma in Q1 2022 and held it in 1 quarter.
Abacus FCF Advisors's Royalty Pharma position peaked at $498K in Q1 2022.
283 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2022.

Based on Abacus FCF Advisors's 13F filing for Q2 2022, filed 20 Jul 2022.